Progenity Inc. (PROG) News
Filter PROG News Items
PROG News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PROG News Highlights
- PROG's 30 day story count now stands at 3.
- Over the past 6 days, the trend for PROG's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about PROG are DRUG.
Latest PROG News From Around the Web
Below are the latest news stories about Progenity Inc that investors may wish to consider to help them evaluate PROG as an investment opportunity.
Progenity Shares Two Poster Presentations on Treatment of Gastrointestinal Disorders at ECCO’22Patient data establishes key correlations for therapeutic exposure in tissue and alternative inflammatory pathways, supporting the hypotheses of targeted therapeutic delivery and potential combination therapy for ulcerative colitisSAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today shared two poster presentations that were presented during the 17th Congre |
Progenity (PROG) Receives a Buy from H.C. WainwrightE…. |
Progenity Shares Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of GastroenterologyDr. Bram Verstockt presented key patient data establishing correlation between drug levels in colon and clinical outcomesSAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today shared an oral presentation that was delivered by Dr. Bram Verstockt during the 34th edition of the Belgian Week of Gastroenterology on February 9, 2022. During the oral presentation t |
10 Stocks to Buy That Could Make You a Millionaire in 2022After this past year, it's going to be hard to find stocks to buy to make you a millionaire in 2022. |
Progenity Strengthens Intellectual Property for Single-Molecule Detection Technology with Additional PatentSAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the award of another new patent related to its single-molecule detection assay platform under development. The USPTO has issued U.S. Patent No. 11,230,731 entitled, “Methods, Systems, and Compositions for Counting Nucleic Acid Molecules.” The issued claims are directed to detecting a labeled target molecule on a solid support. “We have added another important patent t |
Progenity Announces Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of GastroenterologyDr. Bram Verstockt to present patient data establishing correlation between drug levels in colon and clinical outcomesSAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that patient data on indicators of efficacy in the treatment of gastrointestinal disorders has been accepted for oral presentation during the 34th edition of the Belgian Week of |
Progenity Stock’s Hype Cycle Is Over, It Needs ResultsProgenity spent 2021 reinventing itself, dumping its testing laboratory, hiring a new CEO, and refocusing on its patent portfolio. |
Progenity Announces Acceptance of Two Abstracts on Treatment of Gastrointestinal Disorders at ECCO’22SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that two presentations with patient data on indicators of efficacy in the treatment of gastrointestinal disorders have been accepted by the 17th Congress of the European Crohn’s and Colitis Organisation (ECCO), February 16-19, 2022, the world’s largest forum for IBD specialists. ECCO’s mission |
PROG Stock Is a Buy As Progenity Becomes a Leaner CompanyThere's a mismatch as Progenity's patent portfolio keeps growing, yet PROG stock has declined. |
Progenity to Participate in the H.C. Wainwright BIOCONNECT Virtual ConferenceSAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that the company will participate in a pre-recorded presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. The presentation will be available on the conference website beginning at 7 a.m. Eastern / 4 a.m. Pacific on January 10, 2022. A link to the presentation will also be available |